Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 975-982

  Kee, Ji Ye ^a   Ito, Aya ^a   Hojo, Shozo ^a   Hashimoto, Isaya ^a   Igarashi, Yoshiko ^a   Tsukada, Kazuhiro ^a   Irimura, Tatsuro ^d   Shibahara, Naotoshi ^a   Nakayama, Takashi ^b   Yoshie, Osamu ^c   Sakurai, Hiroaki ^a   Saiki, Ikuo ^a   Koizumi, Keiichi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemokine (C X C motif) ligand 16; Colorectal cancer; Liver metastasis; Natural killer T cell

Indexed keywords

CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; GENETIC TRANSFECTION; LIVER METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STABLE EXPRESSION; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CXCL6; COLORECTAL NEOPLASMS; FEMALE; GENETIC THERAPY; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NATURAL KILLER T-CELLS; NEOPLASM TRANSPLANTATION;

EID: 84872825787     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2185     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA and Lu D: Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59: 145-170, 2009.
3. Zlotnik A, Burkhardt AM and Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11: 597-606, 2011.
4. Koizumi K, Hojo S, Akashi T, Yasumoto K and Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98: 1652-1658, 2007. (Pubitemid 47487897)
5. Koizumi K, Kato S, Sakurai H, Hashimoto I, Yasumoto K and Saiki I: Therapeutics target of CXCR4 and its downstream in peritoneal carcinomatosis of gastric cancer. Front Biosci (Schol Ed) 4: 269-276, 2012.
6. Matloubian M, David A, Engel S, Ryan JE and Cyster JG: A transmembrane CXC chemokine is a ligand for HIV coreceptor Bonzo. Nat Immunol 1: 298-304, 2000.
7. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita T and Yonehara S: Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 275: 40663-40666, 2000. (Pubitemid 32054881)
8. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P, Andrew DP, Wu L and Briskin M: Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 166: 5145-5154, 2001. (Pubitemid 32280729)
9. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B, Schuster B, Kallen KJ, Saftig P, Rose-John S and Ludwig A: The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172: 6362-6372, 2004. (Pubitemid 38621245)
10. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ and Raines EW: A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 172: 3678-3685, 2004. (Pubitemid 38337951)
11. Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, Bickett DM, Leesnitzer MA and Becherer JD: Metalloproteinase inhibitors for the disintegrin-like metal-loproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 8: 161-171, 2005. (Pubitemid 40388743)
12. Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, Obermuller N, Doberstein K, Koziolek M, Fritzsche F, Johannsen M, Jung K, Schaider H, Altevogt P, Ludwig A, Pfeilschifter J and Kristiansen G: Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 10: 1016-1023, 2008.
13. Lu Y, Wang J, Xu Y, Koch AE, Cai Z, Chen X, Galson DL, Taichman RS and Zhang J: CXCL16 functions as a novel chemo-tactic factor for prostate cancer cells in vitro. Mol Cancer Res 6: 546-554, 2008. (Pubitemid 351521836)
14. Darash-Yahana M, Gillespie J W, Hewitt SM, Chen YY, Maeda S, Stein I, Singh SP, Bedolla RB, Peled A, Troyer DA, Pikarsky E, Karin M and Farber JM: The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. Plos One 4: e6695, 2009.
15. Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H, Takano Y, Yoshie O, Tsukada K and Saiki I: High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 67: 4725-4731, 2007. (Pubitemid 46910179)
16. Wågsäter D, Hugander A and Dimberg J: Expression of CXCL16 in human rectal cancer. Int J Mol Med 14: 65-69, 2004.
17. Wente MN, Gaida MM, Mayer C, Michalski CW, Haag N, Giese T, Felix K, Bergmann F, Giese NA and Friess H: Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol 33: 297-308, 2008.
18. Ou DL, Chen CL, Lin SB, Hsu CH and Lin LI: Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J Pathol 210: 363-373, 2006. (Pubitemid 44660516)
19. Held-Feindt J, Rehmke B, Mentlein R, Hattermann K, Knerlich F, Hugo HH, Ludwig A and Mehdorn HM: Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas. Glia 56: 764-774, 2008.
20. Seidl H, Richtig E, Tilz H, Stefan M, Schmidbauer U, Asslaber M, Zatloukal K, Herlyn M and Schaider H: Profles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Human Pathol 38: 768-780, 2007. (Pubitemid 46560803)
21. Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese MC, Greenberg HB and Butcher EC: Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extra-lymphoid tissue homing potential. J Clin Invest 107: 595-601, 2001. (Pubitemid 32205180)
22. Kim CH, Johnston B and Butcher EC: Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100: 11-16, 2002. (Pubitemid 35177421)
23. Taniguchi M, Harada M, Kojo S, Nakayama T and Wakao H: The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21: 483-513, 2003. (Pubitemid 37174539)
24. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M and Taniguchi M: Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626, 1997. (Pubitemid 27516281)
25. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y and Taniguchi M: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 95: 5690-5693, 1998. (Pubitemid 28224157)
26. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T and Taniguchi M: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylce-ramide. J Immunol 163: 2387-2391, 1999. (Pubitemid 29399156)
27. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY and Godfrey DI: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191: 661-668, 2000.
28. Cullen R, Germanov E, Shimaoka T and Johnston B: Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. J Immunol 183: 5807-5815, 2009.
29. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M and Seki S: Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166: 6578-6584, 2001. (Pubitemid 32467197)
30. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H and Godfrey DI: Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylce-ramide. Blood 99: 1259-1266, 2002. (Pubitemid 34547079)
31. Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H and Imamura M: Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11: 7322-7327, 2005. (Pubitemid 41507690)
32. Thomas SY, Hou R, Boyson JE, Means TK, Hess C, Olson DP, Strominger JL, Brenner MB, Gumperz JE, Wilson SB and Luster AD: CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 171: 2571-2580, 2003. (Pubitemid 37025568)
33. Johnston B, Kim CH, Soler D, Emoto M and Butcher EC: Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J Immunol 171: 2960-2969. 2003. (Pubitemid 37093518)
34. + NKT cells patrolling liver sinusoids. PLoS Biol 3: e113, 2005.
35. Germanov E, Veinotte L, Cullen R, Chamberlain E, Butcher EC and Johnston B: Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J Immunol 181: 81-91, 2008.
36. Ha HK, Lee W, Park HJ, Lee SD, Lee JZ and Chung MK: Clinical signifcance of CXCL16/CXCR6 expression in patients with prostate cancer. Mol Med Rep 4: 419-424, 2011.
37. Guo L, Cui ZM, Zhang J and Huang Y: Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma. Chin J Cancer 30: 336-343, 2011.
38. Lombardi V, Stock P, Singh AK, Kerzerho J, Yang W, Sullivan BA, Li X, Shiratsuchi T, Hnatiuk NE, Howell AR, Yu KO, Porcelli SA, Tsuji M, Kronenberg M, Wilson SB and Akbari O: A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol 184: 2107-2115, 2010.
39. + lymphocytes to inflamed liver. J Immunol 174: 277-283, 2005. (Pubitemid 40007414)
40. Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M and Adams DH: CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 174: 1055-1062, 2005. (Pubitemid 40094302)
41. + regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol 69: 811-814, 2008.
42. Slettenaar VI and Wilson JL: The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 58: 962-974, 2006. (Pubitemid 44780906)